RenovoRx Inc. Unveils Investor Presentation Highlighting TAMP Therapy Platform and Progress in Pancreatic Cancer Treatment
Reuters
Sep 03, 2025
<a href="https://laohu8.com/S/RNXT">RenovoRx Inc</a>. Unveils Investor Presentation Highlighting TAMP Therapy Platform and Progress in Pancreatic <a href="https://laohu8.com/S/CTHZ">Cancer Treatment</a>
RenovoRx Inc., a NASDAQ-listed company, has shared insights from its recent investor presentation. The company is advancing its proprietary Trans-Arterial Micro-Perfusion (TAMP) platform, which combines RenovoCath with Gemcitabine for treating pancreatic and bile duct cancers. This combination has received FDA Orphan Drug Designation. RenovoRx has initiated the commercialization of its FDA-cleared RenovoCath device, with revenues in the first half of 2025 exceeding expectations. Currently, four cancer centers are using the device, with more than 20 potential customers in discussions. The ongoing Phase III TIGeR-PaC study for locally advanced pancreatic cancer has shown promising results, with a significant reduction in adverse effects. The study's enrollment is expected to conclude by late 2025 or early 2026. RenovoRx aims to pursue a potential peak annual U.S. revenue opportunity of approximately $400 million for RenovoCath as a stand-alone device, with plans to expand its applications further. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief on September 02, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.